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Pluripotent stem cell (pSC)-derived, neural stem cells (NSCs) are actually extensively
explored in the field of neuroregeneration and to clarify disease mechanisms or model
neurological diseases in vitro. Regarding the latter, proliferation and differentiation of
pSC-derived NSCs are investigated under the influence of a variety of different substances
among them key players of inflammation. However, results generated on a murine genetic
background are not always representative for the human situation which increasingly
leads to the application of human cell culture systems derived from human pSCs. We
investigated here, if the recently described interferon gamma (IFNγ)-induced dysregulated
neural phenotype characterized by simultaneous expression of glial and neuronal markers
on murine NSCs (Walter et al., 2011, 2012) can also be found on a human genetic
background. For this purpose, we performed experiments with human embryonic stem
cell-derived NSCs. We could show that the IFNγ-induced dysregulated neural phenotype
cannot be induced in human NSCs. This difference occurs, although typical genes like
signal transducers and activators of transcription 1 (Stat 1) or interferon regulatory
factor 9 (IRF-9) are similarly regulated by IFNγ in both, murine and human populations.
These results illustrate that fundamental differences between murine and human neural
populations exist in vitro, independent of anatomical system-related properties.
Keywords: human neural stem cells, inflammation, interferon-gamma, neurodegeneration, IFNγ
INTRODUCTION
Neural stem cells (NSCs) are multipotent and can give rise to
the three principle cell types found in the adult mammalian
brain, namely neurons, astrocytes, and oligodendrocytes. In vivo,
they can be found in the hippocampus and subventricular zone
where they mainly give rise to new neurons in the dentate gyrus
and olfactory bulb, a process called neurogenesis (Kempermann,
2002, 2011). In vitro, they can be kept under proliferative con-
ditions exhibiting immature neural markers like nestin and Sox2
due to the stimulus of growth factors, or differentiate to the above
mentioned mature cell types when growth factors are withdrawn
(Temple and Qian, 1996; Temple, 2001). Various regenerative
approaches are aimed at using the capacity of NSCs as a therapeu-
tic agent by transplanting them into injured brain regions (Barker
et al., 2003; Harrower and Barker, 2005; Gogel et al., 2011).
Additionally, NSCs from various sources are increasingly used to
simulate diseases in vitro in order to set up model systems that
can easily be manipulated and investigated. A specific and impor-
tant advantage of in vitromodel systems for neurological diseases
is the possibility to use a human genetic background on the basis
of human pluripotent stem cells (pSCs) in order to exclude, for
instance, murine-specific phenomena. One interesting question,
that could be clarified in vitro under controlled conditions, is
how inflammatory processes that consistently occur in various
neurological diseases act on NSCs. As in vivo neurogenesis is
more and more accepted to contribute to processes like, for
instance, memory function (Deng et al., 2009, 2010), it appears
to be of interest to characterize effects of pathological processes
such as inflammation on NSCs. Inflammation itself may lead to
damage in brain tissue and represents either a primary disease
entity or a secondary phenomenon following (Campbell, 2005),
for instance, cerebral ischemia (Whitney et al., 2009). Interferon
gamma (IFNγ), a pro-inflammatory key player, is a cytokine
that is secreted by various cell types such as cytotoxic CD8+
T-cells, natural killer cells (Griffin, 1997), astrocytes, fibroblasts,
and endothelial cells (Rady et al., 1995; De Simone et al., 1998;
Wei et al., 2000). IFNγ signaling takes place via the IFNγ recep-
tor which consists of two chains, situated in the cell membrane
with an extra- and intracellular part (Schreiber and Farrar, 1993).
The structure and the amino acid sequence of the murine and
the human IFNγ protein and its receptor differ, although the
physiological function remains the same (Farrar and Schreiber,
1993). These structural differences are leading to species-specific
IFNγ—IFNγ receptor interactions with human IFNγ affecting
only human and other primate cell types and vice versa (Schreiber
et al., 1992; Schroder et al., 2004). IFNγ receptors were found on
murine NSCs and therefore, effects of IFNγ on murine NSCs and
related alterations in neurogenesis in vivo (Kim et al., 2002; Lin
et al., 2004; Sweeten et al., 2004; Wang et al., 2004, 2008) and
in vitro (Kim et al., 2007; Makela et al., 2010) were excessively
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explored. However, only little is known about the response of
humanNSCs (hNSCs) to IFNγ.We previously investigated effects
of IFNγ on murine embryonic day 14-derived stem/precursor
cells (msNSPCs) and murine embryonic stem cell-derived NSCs
in vitro (Walter et al., 2011, 2012) (both populations are referred
to as mNSCs in the following text). Predominantly in prolifera-
tive mNSC cultures, we found that IFNγ leads to a dysregulated
phenotype, characterized by synchronous expression of neuronal
and glial markers despite the presence of growth factors. This
was accompanied by an unusual electrophysiological phenotype
on single cell level preventing the ability to form synchronously
bursting functional neuronal networks after differentiation. We
also demonstrated an IFNγ-related significant up-regulation of
sonic hedgehog (SHH) and Stat 1, key down-stream signals that
are important for induction of the above mentioned phenotype
(Walter et al., 2012). To assess the relevance of these findings with
respect to the human situation, we (1) treated human embryonic
stem cell-derived hNSCs with this pro-inflammatory cytokine
and (2) measured IFNγ concentrations in cerebrospinal fluid
(CSF) specimens collected from patients suffering from different
nervous system diseases.
RESULTS
hNSCs EXPRESS IFNγ RECEPTOR I AND II
In a first step, we immunocytochemically characterized the
hNSC population generated from immature pluripotent embry-
onic stem cells. After neural pre-differentiation, almost all cells
expressed nestin and most cells (>80%) expressed both, nestin
and Sox2 (Figure 1A). After withdrawal of bFGF, NSCs terminally
differentiated into βIII-tubulin+ neurons or GFAP+ astrocytes
(Figure 1A). As the expression of membrane-bound IFNγ recep-
tors (2 IFNγ receptor-1 chains and 2 IFNγ receptor-2 chains) is
necessary to transduce the IFNγ signal, we performed immuno-
cytochemical labelings against both receptor chains and were
indeed able to demonstrate their expression (Figure 1B). We fur-
ther investigated the expression levels of both receptor chains on
mRNA level by means of real-time quantitative PCR. We com-
pared these data with those generated on a murine background
and found, that murine and human NSCs did not show signifi-
cant differences (Figure 1C). Data were generated with the Wicell
H9 line. We also confirmed these findings by using the HUES
6 line (data not shown).
hNSCs DO NOT EXPRESS THE DYSREGULATED PHENOTYPE AFTER
IFNγ EXPOSURE
One major characteristic of the IFNγ-induced mNSC dysregu-
lation is the coexpression of neuronal and glial markers under
the influence of growth factors that normally hold NSCs in an
immature and proliferating state (Figure 2A). This phenomenon
is visible after a 3-days treatment with 1000U/ml IFNγ and leads
to a portion of around 39% of all cells that co-express GFAP and
βIII-tubulin. The detailed characterization of this phenomenon is
published elsewhere (Walter et al., 2011). However, when imma-
ture and proliferating hNSC populations under the influence of
growth factors were treated with human recombinant IFNγ in
identical concentrations compared to the murine situation, we
were not able to detect this phenomenon (Figure 2A). These
FIGURE 1 | hNSC express IFNγ-RI and IFNγ-RII. In (A) representative
photomicrographs of undifferentiated and differentiated hNSCs (Wicell h9
line) are given. To characterize the undifferentiated stage, proliferating cells
under the influence of growth factors were seeded and then immediately
PFA fixed for immunocytochemistry. To characterize the differentiated
stage, cells were seeded and differentiated for four weeks with an initial
stepwise reduction of growth factors. In the upper panel
immunocytochemical stainings against the neural precursor markers nestin
and Sox2 in undifferentiated hNSCs are given demonstrating that the
pre-differentiation protocol which starts with pluripotent stem cells yields
populations highly enriched in neural precursor cells. In the lower panel
immunocytochemical stainings against βIII-tubulin and GFAP in
differentiated hNSCs are given demonstrating the terminal differentiation
of hNSCs into neurons and astrocytes. In (B) representative
photomicrographs of undifferentiated hNSCs (Wicell h9 line) are given. A
co-immunocytochemical staining against nestin and IFNγ-RI is given in the
upper panel and against nestin and IFNγ-RII in the lower panel showing that
both IFNγ receptor subunits are expressed in undifferentiated hNSCs. In
(C) gene expression levels of IFNγ-RI and IFNγ-RII in undifferentiated
hNSCs (Wicell h9 line) and mNSCs is shown.
Frontiers in Cellular Neuroscience www.frontiersin.org November 2012 | Volume 6 | Article 52 | 2
Walter and Dihné Impact of interferon-gamma on hNSCs
FIGURE 2 | Effects of IFNγ on hNSCs and mNSCs. In (A)
photomicrographs of undifferentiated hNSCs (Wicell h9 line) and mNSCs
are given. A βIII-tubulin and GFAP co-staining under control conditions and
after IFNγ treatment is shown. The upper to panels show mNSCs, the
lower two panels show hNSCs. In mNSCs, IFNγ typically leads to a strong
up-regulation of neuronal (βIII-tubulin) and glial (GFAP) markers with many
cells simultaneously expressing both markers (arrows and the merged
picture). In hNSCs no IFNγ-induced up-regulation of these markers was
detected. In (B) gene expression levels of βIII-tubulin, GFAP, and SHH in
undifferentiated hNSCs (Wicell h9 line) either under control conditions or
after IFNγ treatment are shown. The results demonstrate that there is, also
on mRNA level, no IFNγ-induced up-regulation of cell type-specific markers.
results were also confirmed on mRNA level (Figure 2B). Data
were generated with the Wicell H9 line. We also confirmed these
findings by using the HUES 6 line (data not shown).
IFNγ-REGULATED GENES IN hNSCs AND EFFECTS OF IFNγ ON THE
POPULATION SIZE OF hNSCs
As previously reported, the genes for inducible nitric oxid syn-
thase (i-NOS) (Komatsu et al., 1996), IRF-9 (Ousman et al.,
2005), c-Myc (Ramana et al., 2000), major histocompatibility
complex 1 (MHC 1) (Johansson et al., 2008) and Stat 1 (Lehtonen
et al., 1997) are significantly regulated in murine cells after IFNγ
exposure. We now investigated the expression of these down-
stream signaling genes after IFNγ exposure in hNSCs by means
of real-time quantitative PCR. We found all of these genes to
be significantly up-regulated after IFNγ exposure also in hNSCs
(Figure 3A). As previously reported, we also found SHH to
be significantly up-regulated in mNSCs after IFNγ treatment.
Interestingly, we could not detect that phenomenon in hNSCs.
Another IFNγ-induced phenomenon on a murine background
was a strong reduction of the population size of undifferentiated
mNSCs. However, we were not able to detect a significant decrease
in the population size of hNSCs after IFNγ exposure (Figure 3B).
Data were generated with the Wicell H9 line. We also confirmed
these findings by using the HUES 6 line (data not shown).
IFNγ IS UP-REGULATED IN THE CEREBROSPINAL FLUID OF PATIENTS
SUFFERING FROM DIFFERENT DISEASES
In contrast to the extensively described up-regulation of IFNγ in
animal models of human central nervous system diseases, there is
only very limited information about amounts of IFNγ in human
individuals suffering from neurological diseases. Therefore, we
measured the concentration of IFNγ in cerebrospinal fluid (CSF)
specimens, taken after lumbar punction from patients suffer-
ing from multiple sclerosis, peripheral nervous plexus affections,
Alzheimer dementia, viral myelitis, or stroke. We found, that
patients suffering from multiple sclerosis during an acute relapse
showed a significant increase of IFNγ (three control samples vs.
three MS samples). Due to the limitation of patient material, we
could only screen single patients with other diseases (one patient
per other indicated disease). But also here we found a clear trend
toward an up-regulation of IFNγ in the CSF (Figure 3C).
DISCUSSION
We found here that IFNγ has species-dependent effects on
embryonic stem cell-derived neural populations. While this pro-
inflammatory key player induces a striking dysregulation in
undifferentiated murine neural stem cells (mNSCs) with an
unusual coexpression of neuronal and glial markers (Walter et al.,
2011, 2012), it has no such effects on human NSCs although
both cell populations express appropriate IFNγ receptors and up-
regulate most of the classical down-stream signals like i-NOS,
IRF-9, c-Myc, MHC 1, and Stat 1, which are known to mediate
important IFNγ effects (Schroder et al., 2004).
One possible explanation for this diverse reaction of murine or
human NSCs toward IFNγ exposure might be subtle differences
in their developmental state or brain region-specific differenti-
ation although both populations consist of proliferating nestin-
and Sox2-positive neural precursors. However, the differentiation
protocols used in this study were similar for both species leading
to a heterogeneous population of neural cells without preference
of distinct brain-region specific phenotypes (Illes et al., 2009;
Lappalainen et al., 2010; Yla-Outinen et al., 2010). To account for
developmental differences, we tested additional IFNγ treatment
paradigms for human NSCs including a 7-days treatment or a
5-fold IFNγ concentration but could not detect an up-regulation
of neuronal or glial markers or even the appearance of cells that
synchronously express these markers (data not shown).
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FIGURE 3 | Down-stream gene regulation and population size of
hNSCs after IFNγ exposure and in vivo levels of IFNγ in patients CSF
samples. In (A) gene expression levels in hNSCs (Wicell h9 line) of i-NOS
(inducible nitric oxid synthase), IRF-9 (interferon regulatory factor 9), c-Myc,
MHC1 (major histocompatibility complex 1), and Stat 1 (signal transducers
and activators of transcription 1) are given either under control conditions or
after IFNγ treatment. Results show that IFNγ significantly up-regulates
important down-stream factors except of SHH. Values are means ±
standard error of mean (SEM). Experiments were performed in triplicate
and repeated independently at least three times. In (B) population size of
hNSCs (Wicell h9 line) over 7 days is measured by means of an MTT-assay.
Population sizes of two groups, hNSCs under control conditions or after
IFNγ treatment, are compared. Results show that IFNγ does not affect the
population size of hNSCs. Values are means ± standard error of mean
(SEM). Experiments were performed in triplicate and repeated
independently at least three times. In (C) amounts of IFNγ in clinical CSF
samples are measured by ELISA in comparison to CSF samples of control
patients. For statistical testing of the multiple sclerosis group, 3 control
patients were compared with 3 multiple sclerosis patients [unpaired
two-tailed t-test, value is mean ± standard error of mean (SEM)].
Another explanation for the divergent reactions after IFNγ
exposure might be a qualitatively different induction of down-
stream signals. While SHH is significantly up-regulated after
IFNγ treatment in mNSC populations, it remains unaltered in
hNSC populations. Interestingly, recently published results of our
group show that the IFNγ-induced dysregulated murine phe-
notype depends on both, Stat 1 and SHH signaling (Walter
et al., 2012). Thus, the lack of an important down-stream sig-
nal in the human situation might explain the species-dependent
differences. As it is known that human gliomas and tumori-
genic NSCs express SHH (Ehtesham et al., 2007) and comprise
cells that simultaneously express neuronal and glial markers
(Katsetos et al., 2001; Ignatova et al., 2002; Singh et al., 2003;
Walton et al., 2009), this morphogene was associated with brain
tumor formation and/or growth. Interestingly, in mice a link
between IFNγ and SHH signaling was observed as an ectopic
expression of IFNγ was shown to induce medulloblastoma for-
mation via SHH overexpression (Lin et al., 2004). Our results
in general point to the fact that, possibly fundamental differ-
ences in cytokine-induced signaling pathways between human
and mouse lead to significant differences in the development
of cellular phenotypes. Nevertheless, this type of fundamental
differences can also be observed within a single genetic back-
ground if, for instance, merely the developmental age of a
given cellular population differs. In this regard, several stud-
ies investigated the role of IFNγ in human lymphocyte acti-
vation and found that, depending on their developmental age
(neonatal vs. adult); IFNγ induces divergent down-stream sig-
naling pathways leading to significant differences in their ability
to response to pathogens (Wilson et al., 1986; Marodi et al.,
1994, 2001; Marodi, 2002). Discussed mechanisms for this diver-
gent response of neonatal or adult lymphocytes to IFNγ are a
less effective Stat 1 phosphorylation in neonatal cells or an up-
regulation of a new class of cytokine signaling suppressors that
can inhibit JAK-Stat pathway (Endo et al., 1997; Starr et al.,
1997). In summary, our results admittedly reduce the relevance
of an IFNγ-induced dysregulation of undifferentiated NSCs in a
human genetic background. However, regarding the above men-
tioned considerations, it appears to be possible that human NSCs
of a different developmental stage in comparison to those we
used here can still react to IFNγ exposure with an even mis-
guided initiation of differentiation programs. Thus, our results
can rather be interpreted in a way that a given cellular pop-
ulation in vitro, even on a human genetic background, might
overemphasize results as it not reflects the complexity of an
organism. This consideration is substantiated by observations
from Johansson et al. (2008). In their study, immortalized hip-
pocampal or striatal human neural stem/progenitor cells from
12-weeks-old fetal brains showed increased neurogenesis and
MHC 1 expression after IFNγ exposure during their differen-
tiation phase without growth factors. The divergent results in
comparison to our study might simply be explained by the devel-
opmental stage of the population during IFNγ exposure as we
used proliferating human NSCs under the influence of growth
factors. That human fetal cells are principally able to coexpress
GFAP and βIII-tubulin under non-inflammatory conditions in
the ventricular and subventricular zones as well as under culture
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conditions was shown by Draberova et al. (2008). Probably this
geno- and phenotypic rare case is only possible in a specific
time frame of human fetal development and independent from
inflammatory stimulation.
To further substantiate the relevance of IFNγ during human
CNS diseases, we verified the up-regulation of IFNγ in the
CNS. We demonstrate here that patient CSF contains elevated
amounts of IFNγ in comparison to control CSF of healthy
individuals. Significantly elevated IFNγ levels were found dur-
ing relapses in multiple sclerosis (n = 3) and we also found
increased levels in individual patients suffering from peripheral
nervous plexus affections, Alzheimer dementia, viral myelitis, or
stroke (n = 1, respectively). This is in accordance with the fact
that human peripheral lymphocytes can secrete up to approxi-
mately 200–500U/ml IFNγ under neuroinflammatory conditions
(Hirsch et al., 1985; Chan et al., 1991). As brain ependymal cells
lack tight junctions, the CSF compartment in the brain ventri-
cles exchanges neuroactive substances with the interstitial fluid
of the brain parenchyma, including neurogenic zones (Alvarez-
Buylla and Lim, 2004; Shen et al., 2008; Tavazoie et al., 2008; Ming
and Song, 2011; Hartung and Dihne, 2012). This might point to
a possible anatomical relationship between IFNγ accumulation
within the CSF andNSCs within neurogenic zones, substantiating
the relevance of IFNγ effects on NSCs in humans. In summary,
our results demonstrate that data collected on a murine genetic
background cannot automatically be translated to the human sit-
uation and that even on a human background results might differ
depending on the developmental stage of the population and their
maturation.
MATERIALS AND METHODS
CELL CULTURE
The human NSCs used in this study were either derived from
the human embryonic stem cell lines HUES 6 (hESC facility;
Harvard University; Cambridge, MA, USA) or purchased in a
neuroectodermal, predifferentiated form of the human embry-
onic stem cell line H9 (WiCell Research Institute, Madison,
WI, USA/Invitrogen, Karlsruhe, Germany). The detailed neu-
ronal differentiation protocol is described elsewhere (Dhara
et al., 2008). Use of hESCs for derivation of neural progeni-
tors was approved by the regulatory authorities at the Robert
Koch Institute, Berlin, Germany, and derivation of neural pro-
genitors was performed as follows: the hESCs were cultivated
in knockout serum replacement (KSR) media (Cowan et al.,
2004) on gelatin coated plates and a feeder layer of γ-irradiated
mouse embryonic fibroblasts. Neural differentiation was per-
formed by a protocol previously described by Lappalainen et al.
(2010). Briefly, hESCs were dislodged and separated from the
feeder cells and afterwards dissected into clusters that con-
tained in between 1000 and 3500 cells. These clusters were
placed in neural differentiation/proliferation media that con-
sisted of 1:1 DMEM/F12 and Neurobasal media supplemented
with 2mM GlutaMax, 1XB27, 1XN2, 0.25% BSA, 0.1mM
non-essential amino acids, 25U/ml penicillin/streptomycin (all
products Invitrogen, Karlsruhe, Germany) and 20 ng/ml bFGF
(Tebu-bio, Le Perray en Yvelines Cedex, France). Cells were
propagated for 8–10 weeks with a medium change every 2–3
days, the formed clusters were dissected once per week. After this
time period, the vast majority of cells expressed NSCmarkers like
nestin and Sox 2. Cells were then frozen. For experiments, human
NSC were thawn and single cells were seeded on culture surfaces
that were coated with poly-L-ornithine (PLO; 0.001%; Sigma-
Aldrich, Munich, Germany) and fibronectin (20μg/ml; BioPur,
Bubendorf, Switzerland). In parallel, we used the neuroectoder-
mally pre-differentiated hNSC line (hNSC H9) for comparison.
HNSC H9 cells were cultivated and propagated in the same way
and in the same media as described above. Human NSCs derived
from the cell line H9 were cultivated as free floating clusters and
were dissected to single cells for experiments. The attached cells
were either treated with human recombinant IFNγ (1000U/ml;
Millipore, Billerica, USA) or kept under control conditions for
3 days. This amount is equal to 100 ng/ml recombinant protein
(murine and human). For differentiation experiments, cells had a
day of recovery after seeding, then bFGF was withdrawn from the
cells and differentiation was performed up to 3 months.
IMMUNOCYTOCHEMISTRY
For immunocytochemistry, cells were seeded on coated cover slips
(VWR International, Darmstadt, Germany). After 3 days under
the influence bFGF (20 ng/ml both Tebu-bio) and under different
treatments as indicated, the cells were fixed with 4% PFA (Roti-
Histofix, Carl Roth, Karlsruhe, Germany) for 15min at room
temperature. Cells were blocked for 30min at room temperature
with 1 fold Roti-Immuno-Block containing 0.25% Triton X-100
for cell wall permeabilization (Carl Roth, Karlsruhe, Germany).
Primary antibodies used at 4◦C overnight were against βIII-
tubulin (Tuj1; 1:500; R&D Systems, Minneapolis, USA), glial fib-
rillary acid protein (GFAP) (1:500; Dako, Hamburg, Germany),
Sox2 (1:50; R&D Systems, Minneapolis, USA), IFNγ-R1 (1:500
Santa Cruz Biotechnology, Heidelberg, Germany), IFNγ-R2
(1:500; Santa Cruz Biotechnology, Heidelberg, Germany) and
nestin (1:200; Covance, Munich, Germany). For detection of
primary antibodies, fluoresceine-isothiocyanate (FITC; 1:500;
Millipore, Billerica, USA) or indocarbocyanine (Cy3; 1:800; or
Cy5; 1:200; Millipore, Billerica, USA) coupled secondary anti-
bodies were used. The first and secondary antibodies were
diluted in 1-fold Roti-Immuno-Block without Triton X-100 (Carl
Roth, Karlsruhe, Germany). For visualization of cell nuclei cells
were co-stained with DAPI (Invitrogen, Karlsruhe, Germany).
For negative controls, primary antibodies were omitted in each
experiment.
MTT-ASSAY
To analyze the population size of hNSCs, the optical den-
sity, indicative of conversion of 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) into for-
mazan crystals which takes place in live cells only, was determined
after IFNγ treatment at indicated concentrations. An OD value
of 0.5 represents approximately 50,000 and an OD value of 1.0
represents approximately 100,000 live NSCs. The population size
was measured after the indicated time intervals. Therefore, MTT
(Invitrogen, Karlsruhe, Germany) was added to the cell culture
media at a final concentration of 0.5mg/ml after 5 h of incubation
media was skipped and DMSO (Invitrogen, Karlsruhe, Germany)
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was added for the solubilization of formed crystals. We seeded the
same amount of cells at day 0 and performed an MTT-Assay on
day 3, 5, and 7. At every time point control cells and cells treated
with human recombinant IFNγ were tested. We used the same
dose of human recombinant IFNγ, which was used in the murine
study (1000U/ml).
REAL-TIME QUANTITATIVE PCR
RNeasy Kit (Qiagen, Hilden, Germany) was used for RNA isola-
tion of cultured NSCs. Then a reverse transcription into cDNA
(ABI, Darmstadt, Germany) was performed. Real-time quantita-
tive PCR was carried out by the usage of the 7500 fast or 7500
real-time quantitative PCR cycler (ABI, Darmstadt, Germany).
SYBR green master mix (Qiagen, Hilden, Germany) or equiva-
lent chemistry from another supplier (Quantace, London, UK)
was used. The specific primers for genes of interest or the house-
keeping gene were either purchased (QuantiTect primer assays,
Qiagen) or self-designed (BioTEZ, Berlin, Germany). The genes
of interest (target gene) in IFNγ-treated groups or control groups
(PBS-treated) were analyzed in at least 3 independent cultures
in triplicate each. Every experiment in IFNγ-treated or control
(PBS-treated) groups provided delta CT values (CT: gene of
interest minus reference gene).
STATISTICAL ANALYSES
Experiments were repeated with independent cultures at least
three times in triplicate each. The resulting data sets were
statistically analyzed und illustrated using the GraphPad Prism
4 (GraphPad Software Inc., San Diego, CA, USA, 2003) soft-
ware. For approval of statistical significance between groups, a
two-tailed unpaired t-test was performed. P-values <0.05 were
considered to indicate significant differences.
CSF COLLECTION AND IFNγ ELISA
Lumbar CSF was obtained from patients admitted to our depart-
ment for diagnostic purposes. Patients suffered from multiple
sclerosis (three samples), peripheral nervous plexus affections
(one samples), Alzheimer’s disease (one sample), viral myeli-
tis (one sample), or stroke (one sample), were compared to
control CSF (three samples). All CSF specimens were immedi-
ately centrifuged, aliquoted and stored at –35◦C. Ethics approval
for the use of human CSF was obtained from the institu-
tional ethics committee. For IFNγ detection in the CSF samples
an IFNγ ELISA by R&D systems (R&D systems, Wiesbaden-
Nordenstadt, Germany) was used. The experimental protocol
followed the manufacturer’s instructions. For statistical testing
3 control patients were compared with 3 MS patients with an
unpaired two-tailed t-test.
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